# FibroBiologics, Inc.

**FBLG**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001958777

# None

### No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.76 AUC<br>filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| **Peer failure rate** | 0.60% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | under $12.5M assets<br>total assets $9.6M |
| **Warnings** | dilution, short runway, thin data<br>not computable: degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Mar 13, 2026<br>238 days before the rescan; latest periodic filing 10-Q received Jul 31, 2026 |
| **Last close** | $0.91<br>2026-11-05; market equity $6.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 24, 2026*

We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Our most advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCellTM. We were formed in April 2021 as a Texas limited liability company under the name FibroBiologics, LLC, and converted to a Delaware corporation in December 2021 under the name Fibrobiologics, Inc.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 25.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Return on invested capital | not computable | 9.3% | | | |
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (17.3%) | (6.6%) | 25.1 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 63.4** | | | | | |
| Twelve-month failure probability | not computable | 0.07% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (24.99) | (0.37) | 77.1 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 3.61x | 2.94x | 49.7 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 80.3** | | | | | |
| Revenue growth, three-year compound | not computable | 10.0% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *four consecutive annual FCF observations are required; found 3* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *one or more required annual facts are missing* | | | | | |
| Asset growth, three years | not computable | 2.2% | | | |
| *four annual observations are required; found 3* | | | | | |
| Net share issuance, one year | 79.1% | 2.5% | 80.3 | 630 | 2026-02-24 |

## Warnings

*3 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 79.1% |
| Short runway | cash runway is 2.9 months |
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-05 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | (83.5%) | (2.1%) | 4 |
| Distance from 52-week high | (89.0%) | (30.4%) | 5 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (261.5%) | (1.0%) | 3 |
| Book value to price | 0.73 | 0.29 | 78 |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | not computable | 21.4% | |
| Relative strength against the sector, log excess return | (1.97) | (0.19) | 4 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $3.5M |
| Operating cash flow, four quarters | -$14.8M |
| Months of runway | 2.9 |
| Days since last periodic filing | 98 (10-Q received Jul 31, 2026) |
| Median daily dollar volume, 63 sessions | $168,864 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$18.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$16.4M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 3 | assets | us-gaap:Assets | $9.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 4 | assets | us-gaap:Assets | $16.4M | 2024-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 5 | current assets | us-gaap:AssetsCurrent | $6.3M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $1.8M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$54.2M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$16.6M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 9 | book equity | us-gaap:StockholdersEquity | $6.2M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 10 | liabilities | us-gaap:Liabilities | $3.5M | 2025-12-31 | 2026-02-24 | 10-K | 26-066965 |
| 11 | operating income | us-gaap:OperatingIncomeLoss | -$8.9M | 2023-12-31 | 2025-03-31 | 10-K | 25-001691 |
| 12 | interest expense | us-gaap:InterestExpense | $147,000 | 2023-12-31 | 2024-02-29 | 10-K | 24-008361 |
| 13 | assets | us-gaap:Assets | $11.8M | 2023-12-31 | 2025-03-31 | 10-K | 25-001691 |
| 14 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 67,594,722 | 2026-02-24 | 2026-03-13 | 10-K/A | 26-106216 |
| 15 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 37,735,300 | 2025-03-28 | 2025-03-31 | 10-K | 25-001691 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.